FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:281-282 July 24, 1997 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

To the Editor: The effects of estrogen-replacement therapy on lipid metabolism — mainly, a reduction in levels of low-density lipoprotein (LDL) and modest increases in triglycerides and high-density lipoprotein (HDL) — have been well documented. However, estrogens may prove harmful in women with underlying hypertriglyceridemia, leading to profoundly high triglyceride levels and ensuing pancreatitis.¹ What is less widely known is that tamoxifen, used clinically for its antiestrogenic properties, may have a paradoxical estrogenic effect on lipid metabolism, with the same potential complication.

We describe a 58-year-old woman who was referred for severe hypertriglyceridemia. In July 1992, she underwent segmental mastectomy . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.